Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Argus Health
Cipla
Express Scripts
Mallinckrodt
Harvard Business School

Generated: July 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: RE39706

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: RE39706
Title:Crystalline form of a vitamin D analogue
Abstract:The present invention relates to calcipotriol hydrate--a new crystalline form of calcipotriol--with superior technical properties and with superior stability.
Inventor(s): Hansen; Erik Torngaard (Hundested, DK), Andersen; Niels Smidt Rastrup (Vanlose, DK), Ringborg; Lene Hoffmeyer (Bronshoj, DK)
Assignee: Leo Pharma A/S (Ballerup, DK)
Application Number:10/986,575
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE39706
Patent Claims: 1. Calcipotriol monohydrate characterized by its storage stability at 40.degree. C. after 12 months, its ready wettability and .Iadd.its suitability for .Iaddend.wet ball milling .[.characteristics.]. .

2. Pharmaceutical composition containing the .[.compound.]. .Iadd.calcipotriol monohydrate .Iaddend.of claim 1.

3. Pharmaceutical composition according to claim 2 which is a cream.

4. Pharmaceutical composition according to claim 2 which is a gel.

5. Pharmaceutical composition .Iadd.comprising calcipotriol monohydrate .Iaddend.according to any one of .[.claim 4.]. .Iadd.claims 2-4 and a pharmaceutically acceptable vehicle.Iaddend., with a content of the .[.active component of.]. .Iadd.calcipotriol monohydrate being .Iaddend.1-100 .mu.g/g of the composition.

6. The method of preparing calcipotriol monohydrate which comprises dissolving calcipotriol in organic solvent and then adding water to the resulting solution to precipitate the hydrate, said hydrate being characterized by its storage stability at 40.degree. C., its ready wettability and .Iadd.its suitability for .Iaddend.wet ball milling .[.characteristics.]. .

7. In the preparation of a gel formulation which involves wet ball milling a calcipotriol component and adding the wet milled calcipotriol component to a gel base, the improvement which comprises wet milling calcipotriol hydrate as said component and using this wet milled hydrate for addition to said gel base, said hydrate being characterized by its storage stability at 40.degree. C. after 12 months, its ready wettability and .Iadd.its suitability for .Iaddend.wet ball milling .[.characteristics.]. .

.Iadd.8. Calcipotriol monohydrate according to claim 1, wherein said monohydrate exhibits an infrared spectrum which comprises the following characteristic lines based on the potassium bromide technique: 1455(m), 1442(m), 1330(w), 1290(m), 1210(m), 1085(m), 907(m), 895(m) and 573(w) cm.sup.-1, respectively..Iaddend.

.Iadd.9. Calcipotriol monohydrate according to claim 1 or 8, wherein said monohydrate exhibits a solid state CPMAS .sup.13C NMR spectrum which comprises the following resonances: 147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively..Iaddend.

.Iadd.10. A pharmaceutical composition according to claim 2, wherein said monohydrate exhibits an infrared spectrum which comprises the following characteristic lines based on the potassium bromide technique: 1455(m), 1442(m), 1330(w), 1290(m), 1210(m), 1085(m), 907(m), 895(m) and 573(w) cm.sup.-1, respectively..Iaddend.

.Iadd.11. A pharmaceutical composition according to claim 2 or 10, wherein said monohydrate exhibits a solid state CPMAS .sup.13C NMR spectrum which comprises the following resonances: 147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively..Iaddend.

.Iadd.12. Pharmaceutical composition according to claim 2 which is an ointment..Iaddend.

.Iadd.13. Pharmaceutical composition according to claim 2 which is a lotion..Iaddend.

.Iadd.14. Pharmaceutical composition according to claim 2 which is a solution..Iaddend.

.Iadd.15. Pharmaceutical composition according to claim 2 which is a suspension..Iaddend.

.Iadd.16. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 12 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 .mu.g/g of the composition..Iaddend.

.Iadd.17. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 13 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 .mu.g/g of the composition..Iaddend.

.Iadd.18. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 14 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 .mu.g/g of the composition..Iaddend.

.Iadd.19. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 15 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 .mu.g/g of the composition..Iaddend.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Deloitte
Merck
Daiichi Sankyo
Covington
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.